GlaxoSmithKline (GSK) has received FDA approval for Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The approval is based on the results of the randomized, ...
Tags: advanced soft tissue sarcoma, STS, soft tissue sarcomas, GlaxoSmithKline